Agilent Community Design Infectious Disease Pathogen NGS Panels
Exciting news from Agilent! Pathogen enrichment straight from clinical samples is now possible!
The ability to perform whole genome sequencing of viruses and bacteria directly from clinical samples is important for understanding the genetics of host-pathogen interactions. Due to the much smaller size of pathogen genomes, the proportion of host nucleic acid in an extract massively outweighs that of pathogen nucleic acid.
To overcome this, the research group led by Professor Judith Breuer at University College London has pioneered the enrichment and sequencing of whole pathogen genomes directly from clinical research material using custom SureSelect NGS panels.
“SureSelect target enrichment enables highly efficient whole pathogen genome sequencing without the need for prior culture or PCR. The robust and consistent performance of SureSelect is why we’ve been depending on it for over 10 years.“
The custom designed SureSelect NGS panels targeting the genomes of pathogenic bacteria and viruses provide an effective way to capture nucleic acid material directly from various clinical research samples including blood, sera, plasma, stool, and nasopharyngeal aspirates. This obviates the need of prior enrichment of pathogen by culture or PCR. The SureSelect NGS panel designs created by Professor Breuer’s group are listed in the table below and are now available from Diagnostech. The panels are research tools to study pathogen genome sequences in the context of disease, antimicrobial resistance, treatment and vaccination.
Table 1. The Agilent SureSelect Community Infectious Disease Pathogen NGS panels
|Part Number||Design Name||Targeted Pathogen|
|5191-6721||SureSelect XT Community Design FluA and FluB||Influenza Virus A and B|
|5191-6726||SureSelect XT Community Design PanEnteroRhino||Enterovirus A – D and Rhinovirus|
|5191-6716||SureSelect XT Community Design PanEnterovirus||Enterovirus|
|5191-6719||SureSelect XT Community Design PanHCV||Hepatitis C Virus (HCV)|
|5191-6709||SureSelect XT Community Design PanHIV1||Human Immunodeficiency Virus 1 (HIV-1)|
|5191-6706||SureSelect XT Community Design PanHIV2||Human Immunodeficiency Virus 2 (HIV-2)|
|5191-6714||SureSelect XT Community Design PanNoro||Norovirus|
|5191-6727||SureSelect XT Community Design PanParaflu||ParaInfluenza 1 – 3|
|5191-6722||SureSelect XT Community Design PanRespiratoryViruses||Parainfluenza 1 – 3, Respiratory Syncytial Virus A and B, and Metapneumovirus|
|5191-6725||SureSelect XT Community Design PanRSV||Respiratory Syncytial Virus A and B (RSV-A and RSV-B)|
|5191-6707||SureSelect XT Community Design CMV||Human Cytomegalovirus (HCMV)|
|5191-6711||SureSelect XT Community Design PanHHV6||Human Herpes Virus 6A and B (HHV-6A and 6B)|
|5191-6713||SureSelect XT Community Design PanAdenovirus||Adenovirus|
|5191-6717||SureSelect XT Community Design PanEBV||Epstein-Barr Virus (EBV)|
|5191-6720||SureSelect XT Community Design PanHBV||Hepatitis B Virus (HBV)|
|5191-6728||SureSelect XT Community Design PanHumanPolyomaviruses||Human Polyomaviruses|
|5191-6715||SureSelect XT Community Design PanHSV1and2||Herpes Simplex Virus 1 and 2 (HSV-1 and HSV-2)|
|5191-6718||SureSelect XT Community Design VZV||Varicella Zoster Virus (VZV)|
|5191-6708||SureSelect XT Community Design Ctrachomatis||Chlamydia trachomatis|
|5191-6724||SureSelect XT Community Design Lpneumophila||Legionella pneumophila|
|5191-6710||SureSelect XT Community Design Mtuberculosis||Mycobacterium tuberculosis|
|5191-6723||SureSelect XT Community Design Mtuberculosis Light||Mycobacterium tuberculosis, selected targets|
|5191-6712||SureSelect XT Community Design Nmeningitidis||Neisseria meningitidis|